Our Company

About us

Doctor smiling discussing with patients

Visionary Science

Transforming lives with pioneering ocular gene therapy

Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.

We have an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP) with two preclinical programs, one targeting dry age-related macular degeneration (dAMD) and another targeting cone-rod dystrophy (CRD).

Beacon Therapeutics also has access to a target generation technology platform that will identify, screen and search secreted proteins in the ophthalmology space.

We are supported by funds from Syncona and additional investors including Oxford Science Enterprises.

Father and child building lego structure
Elderly woman smiling while talking to younger woman

Beacon Highlights:

Proprietary pipeline addressing both orphan and prevalent diseases

– Late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP)
– Preclinical programs targeting dry age-related macular degeneration (dry AMD) and cone-rod dystrophy (CRD).

Full R&D-to-clinic capabilities to bring our treatments to patients

– Gene Therapy research teams
– Process and Analytical Development groups
– Regulatory Affairs
– Clinical Development and Clinical Operations

Strategic partnership to secure GMP drug supply

– Beacon commissioned a new state of the art GMP facility in 2023.
– Divested the facility in 2024 and formed a strategic partnership to secure GMP supply of AAV products for tox, clinical and commercial supply.


Image of Dave Fellows, Chief Executive Officer at Beacon

David Fellows

Chief Executive Officer

Image of Dr Nadia Waheed, Chief Medical Officer at Beacon

Dr Nadia Waheed

Chief Medical Officer

Image of Dr Abraham Scaria, Chief Scientific Officer at Beacon

Dr Abraham Scaria

Chief Scientific Officer

Image of Andrew Prosser, Chief Financial Officer at Beacon

Andrew Prosser

Chief Financial Officer

Image of Gwenaelle Pemberton, SVP, Regulatory and Quality at Beacon

Gwenaelle Pemberton

SVP, Regulatory and Quality

Image of Ben Rigby

Ben Rigby

VP, Business Operations

Image of Duncan Whitaker

Duncan Whitaker

SVP, Head of IP and Legal

Join us

Make Remarkable Happen

Beacon Therapeutics is always seeking new talent to join our teams and help deliver our mission to save and restore vision to patients with blinding retinal diseases.

If you are interested in joining our team and have the passion, skills and motivation to be a part of this transformational science, then we are keen to hear from you. Please refer to our careers information.

Explore careers
Researcher working in lab, mixing solutions
Man in lab coat working on computer